Onco360 Selected as National Partner for Beqalzi
BeOne Medicines has tapped Onco360 to provide specialty pharmacy services for its mantle cell lymphoma treatment.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you trust specialty pharmacies to provide better service for complex medication needs than retail pharmacies?
BeOne Medicines has selected Onco360 as a national specialty pharmacy partner for Beqalzi, a treatment for adults with relapsed or refractory mantle cell lymphoma. The drug, which acts as a B-cell lymphoma 2 protein inhibitor, is indicated for patients who have previously undergone at least two lines of systemic therapy.
Why it matters
The partnership aims to streamline access to Beqalzi for patients battling aggressive blood cancers where standard therapies have failed. By targeting the BCL-2 protein, the medication seeks to overcome the chemotherapeutic resistance often developed by cancer cells.
In the BGB-11417-201 clinical study of 103 patients, Beqalzi achieved an overall response rate of 52.4 percent with a median duration of response of 15.8 months. The recommended treatment protocol requires a four-week ramp-up phase followed by a 320 mg daily oral dose.
The players
Onco360
Headquartered in Louisville, Kentucky, this organization is a national specialty pharmacy provider focused on cancer care.
BeOne Medicines
Based in Pennington, New Jersey, this pharmaceutical company develops targeted treatments for oncology patients.
The details
Beqalzi functions by binding to the BCL-2 protein to displace pro-apoptotic proteins, effectively triggering cell apoptosis in cancerous tissue. Patients eligible for this therapy must have previously received treatment including a BTK inhibitor.
Timeline
October 06, 2026: Onco360 was announced as the national specialty pharmacy partner.
The Big Picture
This partnership follows the clinical outcomes established by the BGB-11417-201 clinical study. It marks the commercial expansion phase for a therapy that relies on the specific mechanism of BCL-2 protein inhibition to treat refractory lymphoma.
Patients prescribed Beqalzi will now coordinate with Onco360 for the fulfillment of their 320 mg daily oral dosage. This arrangement aims to standardize the support and delivery process for individuals undergoing the required four-week ramp-up phase of treatment.
The takeaway
The selection of a national specialty pharmacy partner is a critical step in ensuring that patients with refractory mantle cell lymphoma can consistently access complex oral therapies. Patients should consult with their oncology care team to determine if their specific treatment plan incorporates this pharmacy network.
Further reading
For more information on the current treatment landscape for blood-based malignancies, visit our Cancer section.
More information
Learn more about the distribution services and support programs on the Onco360 specialty pharmacy official website.
Live Poll
Do you trust specialty pharmacies to provide better service for complex medication needs than retail pharmacies?
